Welcome to Partnology’s Biotech Leader Spotlight Series, where we highlight the remarkable accomplishments and visionary leadership of biotech industry pioneers. This series is about showcasing the groundbreaking strides made by exceptional leaders who have transformed scientific possibilities into tangible realities. Through insightful interviews, we invite you to join us in following the inspiring journeys of these executives who continue to shape the landscape of the biotech industry. This week we are recognizing:
Niren Shah is the CEO and Co-Founder of Cove Therapeutics, a biotechnology company developing non-viral gene therapies for disorders of the eye, beginning with Stargardt disease. His career spans more than 15 years across biotech leadership, business development, investor relations, medical affairs, and clinical research. Prior to founding Cove in 2021, Niren served as VP/Head of Business Operations and Chief of Staff at Taysha Gene Therapies and held several leadership roles at PTC Therapeutics across strategic partnerships, business development, and investor relations. Earlier in his career, he worked in medical affairs at NPS Pharma and Novartis and began his career in clinical research and academia, serving as an investigator on Phase II–IV clinical trials and as a Clinical Assistant Professor at the University of Florida College of Pharmacy. Niren also serves as an advisor or board member to venture firms, biotech companies, and has previously owned a pair of restaurants which were acquired in 2014.
Cove Therapeutics is tackling one of the biggest challenges in gene therapy through a non-viral, non-lipid nanoparticle delivery approach. For those unfamiliar with the space, what problem are you trying to solve, and why did you believe this was the right company to build?
We started Cove Therapeutics with the idea to solve some of the persistent challenges in gene therapy. My team and I have each been involved in gene therapy for some time, and we’ve been part of programs that have moved from the clinic into the commercial setting. We’ve also worked on transactions in the space, which has given us the unique opportunity to look under the hood at a number of companies, assets, and platforms.
What we’ve seen over the years is that significant challenges in gene therapy still exist. Some stem from biological risks that can lead to safety issues. Others come down to manufacturing—making sure you have a consistent, high-quality product going into the clinic, beginning with first-in-human trials and continuing all the way through commercialization.
While we’ve seen many successful programs, we’ve also been part of situations where gene therapy assets had to be retired because of safety concerns, manufacturing issues, or other biological hurdles. Cove was built to address those challenges through a new platform based on polymer nanoparticles.
With our polymer nanoparticle platform, we believe we can introduce a new paradigm for safety. These polymers are designed to break down and biodegrade without causing the cytotoxicity and inflammation associated with some previous modalities, making safety a key differentiating feature of the platform.
Beyond that, we’ve demonstrated the ability to manufacture these polymer nanoparticles at scale, helping address and de-risk some of the manufacturing challenges the field has historically faced. The platform also has the ability to deliver large genes. Because we’re delivering DNA—and have optimized the platform around DNA delivery and nuclear entry—we have the potential to deliver genetic payloads in a safe and efficient manner compared with previous modalities.
As the platform continues to evolve, we’re seeing the application of different polymer types for various tissue/cell targeting across applications in the eye, muscle, brain, and ear.
Cove is already working with several large pharmaceutical companies before entering human studies. What makes a young biotech an attractive partner at such an early stage?
Delivery has always been a challenge in gene therapy. We have good technologies, but they’re often limited to certain use cases. At the same time, we’ve seen successful gene therapies create truly breakthrough opportunities for patients. The potential to deliver a gene and address a monogenic disorder is incredibly important.
Because of the challenges I mentioned earlier, delivery remains a key focus area not only for us, but also for the large pharma partners we’re engaged with. While Cove continues to de-risk our ophthalmology portfolio, which is our lead franchise, we’re also working with partners to build value in new areas. This includes collaborations with large pharma across the ear, CNS, and muscle, as well as work with other companies to evaluate the delivery of novel cargo into the eye.
We’ve seen encouraging results so far. We’ve demonstrated that new formulations can be used safely and effectively in the ear, and we continue to explore new applications in CNS and muscle. More broadly, the platform has the ability to deliver various types of cargo. We’ve engaged with partners across DNA, mRNA, and combined DNA and mRNA strategies, with promising results.
We’re excited to see where these partnerships can take the platform. As a small company, we’re very focused on building value alongside partners who can help us expand the portfolio and explore the broader potential of the technology.
With an IND expected in the near term for your lead program in Stargardt disease, what does the next 12-18 months look like in terms of proving out the platform?
Stargardt disease is characterized by mutations in ABCA4, and the gene is too large to fit into a traditional viral vector. While there are strategies that use viral approaches to deliver it, we’re coming at it from a different angle: trying to demonstrate better safety compared with previous modalities while also showing that we can efficiently deliver a large gene like ABCA4.
A single injection carrying ABCA4 in our polymer nanoparticle formulation has led to the largest reductions in A2E we’ve seen reported in the field, across both six- and nine-month time points. With those data in hand, we’re moving forward into IND-enabling work, where we’ll further characterize the safety of these nanoparticles and their manufacturability at a much larger scale.
By completing that work, the goal is to move into a Phase 1/2 trial in humans. In that study, we’ll have the ability to assess clinical efficacy by looking at changes in the progression of lesion growth over a 12-month period. Beyond the Stargardt program, we are also advancing novel assets for Geographic Atrophy, wet-AMD, and Usher syndromes. We believe that the unique combination of a novel polymeric platform and suprachoroidal route of administration has the potential to reimagine gene transfer in the eye.
Gene therapy has experienced both tremendous excitement and meaningful setbacks over the past decade. Where do you think the field is headed over the next five years, particularly for non-viral approaches?
I think as the field continues to evolve, there will naturally be use cases where viral vectors work well in certain disease areas, and others where LNPs are particularly effective. But what we believe is that if you can build a platform that works across multiple therapeutic areas, you can unlock a much broader range of indications.
That’s what we’re trying to do—unlock those opportunities through improved safety, the ability to carry large genes, and the potential for durability because we can deliver DNA.
At the same time, while delivery remains a key bottleneck in gene therapy, some of the biological challenges remain as well. One area we’ve focused on is nuclear entry, which I alluded to earlier. Because we can deliver DNA and other nucleic acids, we asked ourselves: how can we more efficiently deliver DNA directly into the nucleus? We’ve optimized around that challenge by adding peptides to our cassettes that help facilitate nuclear entry.
I think we’re at the forefront of trying to solve these delivery challenges, recognizing that they’re made up of many different components. When we started the company, safety was really the primary challenge we wanted to address. As the company has evolved, we’ve recognized other important challenges as well, and we’re now taking those head-on as we continue to develop the platform.
Beyond Stargardt disease, what excites you most about where Cove’s technology could ultimately make an impact?
Stargardt is an important disease because there are currently no FDA-approved products. While some therapies in late-stage development may have disease-modifying properties, we believe ABCA4 gene replacement has the potential to be an important solution for this disease in the future.
While we’re excited about Stargardt, there are also a number of other compelling opportunities. Our second program is focused on geographic atrophy, where the field has already seen progress with anti-complement therapies that are now FDA approved. The question is whether we can build on the efficacy that anti-complement has already demonstrated, and that’s exactly what Cove is trying to do.
We’re developing a first-in-class, dual-mechanism gene therapy for geographic atrophy that combines an anti-complement approach with a neuroprotective gene of interest. The idea is that this dual mechanism could provide additional efficacy beyond what has already been seen in the field—something we consistently hear is important to KOLs.
Behind that, we have programs in wet AMD and Usher syndrome. These are similarly built around the idea that we can deliver large genes, deliver multiple genes, and build upon successes that have already been demonstrated in the field.
Beyond the eye, we’re also really excited about opportunities in the ear, CNS, and other local compartments because they can take advantage of the strategy we’ve already developed for the eye. With delivery into a local compartment, we can focus on selecting polymers that effectively transfect the cells of interest while remaining confined to that compartment, which has the potential to reduce off-target toxicity and inflammation.
When building Cove, how did you think about assembling the right team and board to tackle the scientific and development challenges that come with a novel gene therapy platform?
When we put Cove together, the team was incredibly important. We wanted to find people who were comfortable working on novel platforms, but who also brought deep experience in gene therapy and drug development.
As we’ve built the company, we’ve brought together a team that understands gene therapy from its grassroots—people who have been involved in the field for decades, but who have also had success advancing therapies. Gene therapy isn’t simple or straightforward, so we’ve intentionally surrounded ourselves with people who understand the full development continuum, from discovery all the way through commercialization.
We’ve taken a similar approach to building our board. We have strategic expertise in company building and in taking companies from their earliest stages through growth and ultimately to an exit. But we’ve also assembled a board with deep expertise in ophthalmology and nanotechnology.
Beyond that, we’re fortunate to have board members who understand CNS, muscle, and the ear particularly well, which happen to be areas where we have ongoing collaborations with large pharma. That combination of company-building experience and deep scientific and therapeutic-area expertise has been incredibly valuable as we continue to grow Cove and expand the potential applications of the platform.
Your career spans medical affairs, business development, investor relations, operations, and now CEO. Looking back, which experience has unexpectedly become the most valuable in leading a biotech company?
It’s a tough question to answer because none of it was really by design. I’ve been fortunate to have my career move in different directions, often in ways I never planned, and each of those opportunities has been incredibly valuable.
It’s difficult to point to one specific role or experience that prepared me to make decisions at the executive level. It’s really the culmination of those different experiences that allows me to move flexibly at Cove. Having exposure to medical affairs, late-stage clinical development—including Phase 2 and Phase 3 trials—and the commercial setting has taught me to think with the end goal in mind. That also has to be coupled with understanding how to build and grow a business. Through the years, I have built an understanding of investing across the biotech and tech sectors, either as a private investor or through public securities. This has had a large impact on the way I think about building and growing a business.
That perspective has shaped Cove. We’re constantly thinking about how to take a product from its infancy in discovery all the way through clinical development and, ultimately, to potential commercialization. If you’re not thinking about that end goal from the beginning, it’s difficult to design the right platform, select the right indications, and ultimately identify the right patient populations for clinical trials.
As my career has progressed, I’ve also had the opportunity to work further upstream, which has allowed me to apply those principles across the entire continuum—from discovery to translation, into the clinic, and ultimately into the commercial setting.
I’ve also been fortunate to be part of seven commercial launches during my time at Novartis, NPS Pharma, and PTC Therapeutics. In many ways, I’ve been in the right place at the right time and have had the opportunity to see a lot of products make that journey. Staying close to KOLs and, most importantly, patients has had a significant impact on how I think about drug development. It also helps keep teams motivated and focused on the ultimate goal: delivering meaningful therapies to patients.
